Clinical Trials Directory

Trials / Completed

CompletedNCT05944497

Changes in Pulse Wave Transit Time and Its Variability After Placement of Interscalene Brachial Plexus Block

Changes in Pulse Wave Transit Time and Its Variability Measured From the Ipsilateral First Finger After Placement of Interscalene Brachial Plexus Block

Status
Completed
Phase
Study type
Observational
Enrollment
59 (actual)
Sponsor
JongHae Kim · Academic / Other
Sex
All
Age
20 Years – 60 Years
Healthy volunteers
Not accepted

Summary

Pulse wave transit time (PWTT) increases due to decreased arterial vascular tone resulting from sympathetic blockade caused by regional anesthesia. Its oscillation (PWTT variability) also contains information on the interaction between autonomic nervous system and the cardiovascular system. The changes in PWTT and its variability have not been investigated in patients receiving interscalene brachial plexus block (ISBPB). It was hypothesized that ISBPB increases PWTT and reduces low frequency power of PWTT variability.

Conditions

Interventions

TypeNameDescription
PROCEDUREInterscalene brachial plexus blockUsing a linear ultrasound transducer connected to an ultrasound machine, the compactly arranged brachial plexus is visualized lateral to the pulsating subclavian artery. The transducer is moved cephalad to visualize the 5th to 8th cervical (C5 to C8) nerve roots located between the anterior and middle scalene muscles. Using an in-plane technique, a block needle is inserted close to a nerve root in a lateral-to-medial direction. The needle is moved to place 0.75% ropivacaine around each nerve root. The C8 nerve root is blocked first, and the C5 nerve root is blocked last. After blocking the four cervical nerve roots, ropivacaine is placed in the intermuscular plane between the sternocleidomastoid and scalene muscles to block the supraclavicular nerves. A total of 26 ml of 0.75% ropivacaine is used for the interscalene brachial plexus block (6 ml per nerve root and 2 ml for the supraclavicular nerves).

Timeline

Start date
2023-07-31
Primary completion
2024-01-07
Completion
2024-01-07
First posted
2023-07-13
Last updated
2024-01-23

Locations

1 site across 1 country: South Korea

Source: ClinicalTrials.gov record NCT05944497. Inclusion in this directory is not an endorsement.